(redirected from matrix metalloproteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
BB-3644 is a second-generation matrix metalloproteinase inhibitor.
Matrix metalloproteinase inhibitors have been in development by British Biotech for the past 12 years.
Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer; BB-3644, a follow-on to marimastat, is in Phase I development for cancer; BB-10153 has completed Phase I development for cardiovascular disease; BB-2827, a collagenase inhibitor for inflammation, is in Phase I development; and E21R, a modified GM-CSF, has completed Phase I development.
Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases [Electronic version].
They cover carbonic anhydrase inhibitors and activators, matrix metalloproteinase inhibitors, bacterial zinc protease inhibitors, and other enzymes containing zinc.
matrix metalloproteinase inhibitors, multidrug resistance inhibitors, antisense oligonucleotides) have failed to fulfill their promise to date.
Additionally, the Company's MultiStat([R]) compounds have been shown to be 1,000 times more potent than the natural matrix metalloproteinase inhibitors that are present in human blood and some plant extracts.
MultiStat is Quick-Med's proprietary family of compounds - generally called Matrix Metalloproteinase Inhibitors - that represent a new frontier in anti-aging skin care.

Full browser ?